TABLE 3.
Plasma cholesterol, TGs, and cholesterol precursor at baseline and after 7 weeks of treatment
| Treatment (n = 39) | Baseline | Placebo | 10 mg Ezetimibe | 20 mg Simvastatin | 10 mg Ezetimibe + 20 mg Simvastatin |
|---|---|---|---|---|---|
| Parameter (mg/dL) | Least Squares Mean Percentage Change from Baseline (±SE) |
||||
| TC | 228.6 | 1.7a (10.4) | −13.8b (8.70) | −26.4c (9.6) | −38.1d (8.6) |
| LDL-C | 152.1 | 2.6a (12.9) | −20.0b (10.6) | −38.1c (12.2) | −55.0d (10.4) |
| NonHDL-C | 177.7 | 1.6a (12.8) | −19.3b (8.9) | −35.5c (11.1) | −57.7d (10.1) |
| HDL-C | 50.9 | 2.4a (10.9) | 5.2a (12.5) | 6.0b (12.3) | 9.6b (11.5) |
| Median Percentage Change from Baseline (±SE) | |||||
| TG | 128.5 | −7.1a (38.5) | −10.7a (23.6) | −21.0b (29.2) | −30.8c (23.0) |
Within each parameter, if the superscript letters for the means of treatments are the same, they are not statistically significantly different. If the letters are different, the means are significantly different at the P ≤ 0.001 level.